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doi:10.1016/j.ejvs.2009.09.003Abstract Objective: This study aims to compare the antibacterial activities of vascular pros-
theses: silver-impregnated and modified with covalently immobilised antibiotics.
Materials and Methods: Six types of protein-sealed vascular prostheses were modified with
amikacin and gentamicin according to the method described in the Polish Patent Office. Their
antimicrobial properties were estimated against 14 reference and clinical strains and
compared with those of InterGard Silver grafts. Cytotoxicity of the tested grafts was
estimated against human skin fibroblasts.
Results: Prostheses modified with antibiotics in a stable covalent mode were found to be much
more effective against bacterial growth and biofilm formation, as well as in case of methicillin-
resistant Staphylococcus aureus (MRSA), than InterGard Silver. They inhibited the bacterial
growth for at least 30 days, without losing higher than 10% of the initial amount of its drug
content. They were also good, non-toxic matrices for growth of human skin fibroblasts.
Conclusions: Prostheses modified with covalently immobilised antibiotic according to our tech-
nique are much more effective than InterGard Silver at protection against bacterial growth.
They are also compatible with human skin fibroblasts.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Vascular surgery of the 21st century still faces many prob-
lems, including those concerning the postoperative infec-
tions of implanted vascular prostheses. Reports presentub.pl (A. Belcarz).
ty for Vascular Surgery. Publishea low incidence of vascular graft infections (0.5e5% of all
cases)1,2; however, they are associated with 12e27%
mortality and 10e15% limb amputation rates when it
concerns infrarenal and femoral arteries.3 Microbial attack
is specially dangerous in relation to cell adhesion and bio-
film formation on the implant surface. The cells entrapped
within the biofilm form complex communities4 of enhancedd by Elsevier Ltd. All rights reserved.
Table 1 Description of prostheses used in experiments.
Prosthesis Manufacturer Material
1. Hemashield
Gold
Boston
Scientific, USA
Polyesterþ
collagen
2. Wovex Bard, Cardial,
France
Polyesterþ
collagen
3. Gelsoft Vascutek,
Scotland
Polyesterþ
gelatin
4. UniGraft
DV straight
Braun Melsungen
AG, Germany
Polyester (PET)þ
gelatin
5. Tricogel Tricomed, Poland Polyester (PET)þ
gelatin
6. InterGard
Silver
InterVascular,
France
Polyesterþ
collagen/silver
698 M. Osin´ska-Jaroszuk et al.resistance to antibiotics; they become 10e1000 times less
sensitive to antimicrobial agents than do planktonic cells.5
Conventional management of infected vascular grafts
includes total graft excision combined with debridement of
adjacent native artery, replacement by a new prosthesis or
bypass grafting and aggressive systemic antibiotic admin-
istration. Effectiveness of antibiotic therapy, however,
depends on location, extent of infection, the type of the
infecting microorganism and its sensitivity to the applied
antibiotic.6,7 Early-onset infections are generally caused by
Staphylococcus aureus (a representative of coagulase-
positive staphylococci), while late-onset infections are
caused by coagulase-negative biofilm-producing Staphylo-
coccus epidermidis, although recently it was observed that
mixed infections were more prevalent.8 In current estima-
tions, S. aureus, S. epidermidis and Escherichia coli are
responsible for approximately 75% of wound/graft infec-
tions.9 Moreover, remember that antimicrobial resistance
among bacteria is an increasing threat.10 Among Staphylo-
cocci, for example, methicillin-resistant S. aureus (MRSA) is
responsible for over 50% of infections in vascular surgery
procedures, open reduction of fracture of long bones and
limb amputation cases.11
Graft infections may be reduced by using modified
vascular prostheses of increased antimicrobial activity.
Such grafts are produced by soaking commercially available
prostheses into antibiotics solutions (e.g., in case of
rifampicin-soaked protein-sealed grafts12). However, the
drug is quickly eluted from such prostheses when incubated
in liquid. Some research groups attempted to increase the
antibacterial activity of vascular prostheses by prebonding
of polyester grafts previously activated by succinylated
gelatin with two antibiotics (rifampin and tobramycin).13
The effect of antibiotics absorbed into vascular grafts may
also be increased by simultaneously applying lipopeptides
bearing antimicrobial activity against a large number of
Gram-positive cocci.14 However, despite these promising
concepts, there is still a need for producing prostheses
which would retain significant antibacterial activity for
longer than 1 month, thus preserving them from early as
well as late bacterial infections.
An alternative strategy for enhancing antimicrobial
effects of vascular grafts is their impregnation by silver
salts. Silver ions exert bactericidal activity on DNA, protein
and membrane levels through several mechanisms.15,16
Efficacy of silver-impregnated prostheses in combating
vascular implant infections was reported in numerous
articles.17e21 On the other hand, there are also some reports
stating that the positive role of silver in preventing infec-
tions is rare or controversial.22e26 Bactericidal properties of
silver salts are even increased in the presence of rifampin in
comparison with the antibiotic alone.27 However, the long-
term activity of silver-coupled grafts seems to be ineffi-
cient, similarly to antibiotic-soaked prostheses that quickly
elute the majority of adsorbed drug.
We have already reported the effectiveness of pros-
theses modified with covalently immobilised aminoglyco-
side antibiotics,28,29 which showed a long-lasting
antibacterial activity. Some of their advantages have been
highlighted: stability during sterilisation and long-term
storage, cytocompatibility and others. In some in vitro
experiments, we have found that these prostheses aremuch more efficient at protecting themselves and the
surrounding medium against bacterial attack than not just
non-modified grafts but also commercially available silver-
impregnated prostheses used in vascular surgery as one of
the most frequently applied modified matrices showing
antibacterial properties. This study presents the results of
comparison of antibacterial properties between protein-
sealed vascular prostheses with covalently immobilised
aminoglycoside antibiotics and silver-impregnated
prostheses.
Materials and Methods
Media and strains
Bacterial growth inhibition was tested on Mu¨ellereHinton
(MeH) broth, Mu¨ellereHinton (MeH) agar II medium (both
from Oxoid Ltd., England) or liquid LuriaeBertani (LB) broth
(Biocorp, Poland).
Bacterial strains were stored in microbanks (PRO-LAB
Diagnostics, UK). Reference strains were: E. coli ATCC
25922, Pseudomonas aeruginosa ATCC 27853, S. aureus
ATCC 25923. Clinical strains were isolated in the Clinical
Hospitals in Lublin, Poland: E. coli from ear, urinary tract
and faeces; E. coli 262 amikacin-resistant (MIC
500 mg ml1); P. aeruginosa from eyelid; ESBL (extended-
spectrum b-lactamase) P. aeruginosa; S. aureus from throat
and faeces; S. aureus MR3 (methicillin-resistant); S. aureus
S1 (ampicillin-resistant); S. epidermidis from skin. The
choice of the bacterial strains was based on literature data,
as the strains are claimed to be responsible for majority of
vascular graft infections.30,31
The vascular prostheses used in the experiments are
listed in Table 1.
Gentamicin sulphate and amikacin sulphate (Biodacyna)
for immobilisation (40 mgml1 and 250 mgml1, respec-
tively) were supplied by KRKA (Croatia) and Bioton
(Poland), respectively. Standards for gentamicin and ami-
kacin measurements were obtained from Fluka (1 mgml1)
and the Institute of Biotechnology and Antibiotics, Warsaw
(Poland), respectively.
Reagents for culture tests were supplied by Sigma (USA),
unless otherwise stated.
Table 2 Results of gentamicin and amikacin immobilisa-
tion to protein-sealed vascular prostheses.
Type of
prosthesis
Gentamicin
bound to
prosthesis (mg/g)
Amikacin bound
to prosthesis
(mg/g)
1. Hemashield
Gold
1.14 0.7 2.48 0.03
2. Wovex 2.52 0.9 3.12 0.65
3. Gelsoft 4.02 0.7 5.12 0.6
4. UniGraft DV
straight
4.02 0.6 6.24 0.7
5. Tricogel 3.64 0.3 4.64 0.8
Vascular Prostheses with Covalently Bound Gentamicin and Amikacin 699All other reagents (of analytical or HPLC grade) were
obtained from Merck (Germany) and Fluka (Switzerland).
Covalent immobilisation of antibiotics on vascular
prostheses and drug release
Covalent immobilisation of gentamicin and amikacin on
commercial protein-sealed vascular prostheses (Table 1)
was performed according to the procedure described in the
Polish Patent no. P358934.32 Briefly, the first step of the
reaction included the prosthesis activation with glutaral-
dehyde; second, antibiotic reaction with activated matrix,
followed by reduction of Schiff bases by NaBH4. An antibi-
otics solution of 2.5 mgml1 in 12 ml per 1 g of prosthesis
was used for immobilisation. The amount of antibiotics
both bound to prosthesis and released to phosphate-buff-
ered solution (PBS) in drug release tests was estimated by
high performance liquid chromatography (HPLC) or ultra-
violet (UV) spectrophotometric assays, as described
elsewhere.28,29
In vitro drug release test was performed on five pieces
(50 mg) of modified prosthesis with 20 ml sterile PBS, pH
7.4, shaken in Erlenmayer flasks at 37 C for 30 days. The
PBS was exchanged every week and assayed for antibiotic
content. The test was performed in triplicate.
Inhibition of bacterial growth and biofilm formation
Antibacterial activity of the selected prostheses modified
by antibiotics or impregnated with silver (InterGard
Silver) was estimated by the following methods:
e using spot test, as described elsewhere,28 with an
exception that MeH agar II medium was used.
e by incubation of a 1-cm2 fragment of modified pros-
thesis in 20 ml sterile liquid LB broth supplemented
with bacterial inoculate to appropriate final CFU
(colony forming units) ml1, for 30 days, under gentle
shaking (35 rpm) at 37 C. The medium was exchanged
every 7 days with simultaneous supplementation with
appropriate bacterial inoculate. Concentration of
bacteria in medium samples was estimated every week
using the overall count of bacteria by a serial dilution
method. All experiments were performed in triplicate.
Subsequently, all 1-cm2 fragments of vascular prostheses
covalently modified with antibiotics or InterGard Silver,
incubated with bacteria-containing media for 30 days, were
estimated for biofilm presence using 2,3,5-triphenylte-
trazolium chloride (TTC). For this purpose, they were
extensively washed with sterile distilled water to remove
all non-adhered cells and placed in sterile tubes containing
5 ml MeH broth supplemented with 15 ml 1% TTC solution.
The tubes were then incubated for 18 h at 37 C and esti-
mated for appearance of red formazan dye, indicating the
reduction of TTC by living bacterial cells.
Stability of antibacterial activity of
vascular prostheses
Stability of antibacterial activity was assayed against
reference bacterial strains: E. coli ATCC 25922,P. aeruginosa ATCC 27853, S. aureus ATCC 25923. Liquid LB
medium (5 ml) containing 1-cm2 sterile fragment of each
prosthesis was supplemented with 5 ml of 1 106 inoculum
of each type of bacteria. Media were incubated for 30 days
at 37 C with quotidian exchange of medium and inocula-
tion with a fresh dose of bacteria. OD550nm was measured
every week as a function of turbidity caused by bacterial
propagation.
Cell culture
Human skin fibroblasts (HSFs) were grown in a culture
medium (Dulbecco’s minimum essential medium (DMEM)
containing 10% foetal bovine serum (FBS), 100 Uml1
penicillin and 100 mgml1 streptomycin). Pieces of
vascular prostheses modified with gentamicin and amikacin
were placed in a 24-well microplate (Nunc, Denmark) and
incubated in a culture medium at 37 C, 5% CO2, overnight.
The medium was then removed and replaced by 3 104 HSF
suspension in the culture medium. Starting at 48 h, the
culture medium was changed daily. Cytotoxicity of the
tested prostheses was estimated in the culture medium
after 24 h of growth, as a function of LDH activity released
from the cells in the presence of prostheses, using LDH
Cytotoxicity Detection Kit (Roche Diagnostics,
Switzerland). Presence of HSF on prostheses (after 120 h of
culture) was detected by confocal microscopy, after
washing twice in sterile PBS and subsequently staining with
3,30-dihexyloxacarbocyanine iodide. Specimens were
examined using confocal microscope LSM-5 (Zeiss,
Germany) at 514 nm.
Results
Covalent immobilisation of antibiotics on vascular
prostheses and drug release
The results of amikacin and gentamicin immobilisation to
six types of protein-sealed vascular prostheses showed
that, among the tested grafts, gelatin-sealed matrices were
able to bind more drug than collagen-coated matrices
(Table 2). It was also shown that amikacin was bound to
matrices in higher amounts than gentamicin, which was
demonstrated for each prosthesis (Table 2). UniGraft was
the optimal matrix for binding of both antibiotics (Table 2).
700 M. Osin´ska-Jaroszuk et al.As the best results of antibiotics immobilisation were
obtained for UniGraft prosthesis, the results of other tests
were demonstrated for these prostheses with covalently
immobilised amikacin and gentamicin and compared with
those of InterGard Silver.
Drug release test revealed that the much of the immo-
bilised antibiotics was stable while only some amount of
drug had been released to the surrounding medium during
30 days of the tests (Table 3). Antibiotics immobilised to
prostheses, according to the patented method for creation
of covalent bonds, remained on the matrix in approxi-
mately 90% of the initial amount after 30 days.
Inhibition of bacterial growth and biofilm formation
Inhibition of bacterial growth by prostheses modified with
antibiotics and InterGard Silver was demonstrated in
contact with both solid and liquid media. The prosthesis
selected for these tests was UniGraft, showing the best
results of antibiotic binding among all tested biomaterials.
Reaction of vascular graft fragments with infected agar
medium mimicked the conditions of direct prosthesise
bacteria contact (Fig. 1). It was shown that both genta-
micin- and amikacin-modified prostheses revealed the
ability to inhibit bacterial growth, as demonstrated by the
presence of growth inhibition zones (Fig. 1, A1e3 and
B1e3). The fact that these zones are of small dimensions is
in agreement with the results of drug release tests, which
showed that the majority of antibiotic was bound by strong
covalent bonds and only approximately 10% by weak and
easily diffusing interactions. On the contrary, silver-
impregnated prostheses did not evoke such effect and no
bacterial growth inhibition zone was observed around these
grafts (Fig. 1 and C1e3). However, when fragments of
InterGard Silver prostheses were lifted above the infected
agar medium, the places free of bacteria appeared on the
surface of the medium (Fig. 1, Insert C10).
A comparative study on antibacterial activity of tested
prostheses was also performed in liquid media supple-
mented with reference bacterial strains or clinical isolatesTable 3 Comparison of amounts of antibiotics remaining on co
days, 37 C, PBS) and rifampicin-adsorbed prostheses cited in
according to our method, 3*e5* e rifampicin-adsorbed prosthese
Days Amount of antibiotic remaining on prosthesis (mg/g)
Own results (R
1 2 3
Gentamicin;
gelatin-sealed
UniGraft, Germany
Amikacin;
gelatin-sealed
UniGraft, Germany
R
a
V
0AI 11.01 6.79 1
1 10.90 6.75
7 10.87 6.53
14 10.87 6.53
21 10.85 6.53
30 10.85 6.53
AI amounts observed directly after immobilization.from surgical tracts. The general tendency has shown that
covalently modified UniGraft prostheses, containing
either gentamicin or amikacin, were able to inhibit growth
of tested bacterial strains, also clinical isolates, with just
a few exceptions (Tables 4 and 5). They concerned two
reference strains: S. aureus, propagating in presence of
both prostheses and P. aeruginosa, growing in presence of
amikacin-modified graft. This effect, however, was
observed only when huge bacterial concentration (4 108)
was applied. Moreover, it should be noted that, despite
the bacterial growth, the inhibiting activity of released
antibiotic has been observed in the early period of
experiment (Table 4). Amikacin-modified prostheses were
unable to inhibit bacterial propagation only in case of two
E. coli clinical isolates, while those containing gentamicin
revealed bactericidal activity against all tested clinical
strains. By contrast, InterGard Silver revealed only
scarce antibacterial activity, mainly limited to the first day
of experiment; subsequently, all tested bacteria grew
abundantly in presence of InterGard Silver grafts (Tables
4 and 5).
Biofilm presence on tested prostheses was estimated
after extensive washing to remove all non-adsorbed
bacterial cells prior to placing in fresh TTC-supplemented
medium. Therefore, presence of formazan could have
appeared only in case of prostheses colonised by bacte-
rial biofilm. It was found that biofilm was detected on
control non-modified UniGraft and InterGard Silver
grafts while covalently modified UniGraft prostheses,
containing gentamicin and amikacin, remained untouched
by biofilm.
Stability of antibacterial activity of
vascular prostheses
Stability of antibacterial activity of InterGard Silver and
antibiotic-modified UniGraft prostheses showed that,
despite quotidian change of medium with simultaneous
supplementation with bacterial inoculate gentamicin- and
amikacin-modified grafts were able to continuously inhibitvalently modified PET vascular prostheses during elution (30
literature. 1e2 e UniGraft prostheses covalently modified
s (results cited by Lovering & MacGowan12).
after elution
esults cited by Lovering & MacGowan12)
* 4* 5*
ifampicin;
lbumin-sealed,
asculour, USA
Rifampicin;
collagen-sealed
Hemashield, USA
Rifampicin;
collagen-sealed
Cardial, USA
0.689 7.174 7.424
0.0853 0.0022 0.024
0.0042 0.0008 0.0007
0 0 0
0 0 0
0 0 0
Figure 1 Inhibition of bacterial growth by UniGraft prostheses covalently modified with gentamicin (A1eA3) and amikacin
(B1eB3) versus InterGardTM Silver (C1eC3) grafts. 1 e E. coli ATCC 25922; 2 e S. aureus ATCC 25923; 3 e P. aeruginosa ATCC 27853.
Insert C10 - plate with the fragments of prosthesis lifted up above infected agar medium, showing the places where bacterial growth
was inhibited.
Vascular Prostheses with Covalently Bound Gentamicin and Amikacin 701the growth of reference strains. Under the same conditions,
InterGard Silver prostheses revealed only slight antibac-
terial effects; their bactericidal activity was significantly
limited in comparison with covalently modified prostheses
(Fig. 3).Figure 2 E. coli ATCC 25922 biofilm formation on vascular prost
modified control; 2 e InterGardTM Silver; 3 e amikacin-modified UCell culture
The ability of human skin fibroblasts to grow on vascular
prostheses was tested in our experiments only for grafts
covalently modified with gentamicin and amikacin, asheses. (TTC reduction method, 24 h, 37 C). 1 e UniGraft no
niGraft; 4 e gentamicin-modified UniGraft.
Table 4 Inhibition of growth of reference bacterial strains in presence of antibiotic-modified grafts versus silver-impregnated prostheses. Medium inoculated to a final
bacteria concentrations as shown in the Table was exchanged every week. Bacteria: E. coli ATCC 25922; P. aeruginosa ATCC 27853; S. aureus ATCC 25923. (MICs in brackets).
Type of
prosthesis
Strain (MIC mg/
ml)
Initial CFU/ml Concentration of bacteria (CFU/ml)
Day 1 Day 7 Day 14 Day 21 Day 30
UniGraft
modified by
gentamicin
(9.5 mg/g
prosthesis)
E. coli (5) 1 104 0 0 0 0 0
4 108 0 0 0 0 0
P. aeruginosa
(10)
1 104 0 0 0 0 0
4 108 0 0 0 0 0
S. aureus (10) 1 104 0 0 0 0 0
4 108 1.2 107 0.15 1.3 108 0.15 1.3 108 0.15 1.3 108 0.15 1.3 108 0.15
UniGraft
modified by
amikamicin
(9.7 mg/g
prosthesis)
E. coli (5) 1 104 0 0 0 0 0
4 108 0 0 0 0 0
P. aeruginosa
(10)
1 104 0 0 0 0 0
4 108 0 0 6.6 107 0.15 6.6 107 0.15 6.6 107 0.15
S. aureus (10) 1 104 0 0 0 0 0
4 108 0 0 7.0 107 0.2 7.0 107 0.2 7.0 107 0.2
InterGard
Silver
E. coli 1 104 1.2 104 0.1 1.2 109 0.15 1.2 109 0.15 1.2 109 0.15 1.2 109 0.15
4 x 108 1.2 109 0.15 1.2 109 0.15 1.2 109 0.15 1.2 109 0.15 1.2 109 0.15
P. aeruginosa 1 x 104 0 7.2 108 0.2 7.2 108 0.2 7.2 108 0.2 7.2 108 0.2
4 108 1.2 109 0.2 1.2 109 0.2 1.2 109 0.2 1.2 109 0.2 1.2 109 0.2
S. aureus 1 104 1.2 105 0.1 1.2 109 0.15 1.2 109 0.15 1.2 109 0.15 1.2 109 0.15
4 108 1.2 105 0.1 1.2 109 0.15 1.2 109 0.15 1.2 109 0.15 1.2 109 0.15
702
M
.
O
sin´
ska
-Ja
ro
szu
k
e
t
a
l.
Table 5 Inhibition of growth of clinical bacterial isolates in presence of antibiotic-modified grafts versus silver-impregnated
prostheses. Medium inoculated to a final bacteria concentrations as shown in the Table was exchanged every week. (MICs in
brackets). Initial CFU/ml of all bacterial suspensions in LuriaeBertani medium: 1 105.
Type of prosthesis Strain
(MIC mg/ml)
Concentration of bacteria (CFU/ml)
Day 1 Day 7 Day 14 Day 21 Day 30
UniGraft modified
by gentamicin
(9.5 mg/g prosthesis)
E. coli, ear (5) 0 0 0 0 0
E. coli, urinary
tract (20)
0 0 0 0 0
E. coli, faeces (5) 0 0 0 0 0
P. aeruginosa,
eyelid (5)
0 0 0 0 0
S. aureus,
throat (5)
0 0 0 0 0
S. aureus,
faeces (5)
0 0 0 0 0
S. aureus
MR3a(5)
0 0 0 0 0
S. epidermidis,
skin (2)
0 0 0 0 0
UniGraft modified
by amikamicin
(9.7 mg/g prosthesis)
E. coli; ear (5) 0 5.0 108 0.2 >109 >109 > 109
E. coli; urinary
tract (20)
0 0 0 0 0
E. coli;
faeces (5)
0 0 0 0 0
E. coli; AR
262b (5)
5.0 108 0.2 >109 >109 >109 > 109
P. aeruginosa;
ESBLc (10)
0 0 0 0 0
S. aureus S1d (5) 0 0 0 0 0
S. aureus
MR3 (10)
0 0 0 0 0
S. epidermidis;
skin (5)
0 0 0 0 0
InterGard Silver E. coli; ear 1.2 105 0.1 1.2 109 0.2 1.2 109 0.2 1.2 109 0.2 1.2 109 0.2
E. coli; urinary
tract
1.4 105 0.1 1.2 109 0.2 1.2 109 0.2 1.2 109 0.2 1.2 109 0.2
E. coli; faeces 1.4 105 0.1 1.4 109 0.2 1.4 109 0.2 1.4 109 0.2 1.4 109 0.2
E. coli; AR 262 8.4 104 1.0 8.4 108 2.0 8.4 108 2.0 8.4 108 2.0 8.4 108 2.0
P. aeruginosa;
ESBL
2.4 102 0.5 6.8 108 2.0 6.8 108 2.0 6.8 108 2.0 6.8 108 2.0
S. aureus; S1 0 5.6 108 2.0 5.6 108 2.0 5.6 108 2.0 5.6 108 2.0
S. aureus; MR3 0 6.8 108 2.0 6.8 x 108 2.0 6.8 108 2.0 6.8 108 2.0
S. epidermidis;
skin
0 2.2 108 2.0 2.2 108 2.0 2.2 108 2.0 2.2 108 2.0
a S. aureus methicillin-resistant.
b E. coli 262 amikacin-resistant.
c P. aeruginosa extended-spectrum b-lactamase.
d S. aureus ampicilin-resistant.
Vascular Prostheses with Covalently Bound Gentamicin and Amikacin 703InterGard Silver prostheses was carefully examined by
manufacturer as a matrix for human cell attachment. The
results showed that HSF cells grew easily on both non-
modified and antibiotic-modified UniGraft prostheses
(Fig. 4). The cytotoxicity test on osteoblasts cultured in
the presence of vascular grafts did not show any statisti-
cally significant increased release of LDH to the
surrounding medium (103%) in comparison with control
containing HSF without prostheses (100%). This indicatedthe lack of cytotoxicity of the tested antibiotic-modified
biomaterials.
Discussion
Vascular aortic infection is one of the most serious
complications in postoperative arterial surgery treatment.
Short-term infection is easier to fight when antimicrobially
modified (with silver or antibiotic) biomaterials are used
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E. coli S. aureus P. aeruginosa
Figure 3 Stability of antibiotic-modified UniGraft vascular prostheses against InterGardTM Silver grafts. Bacterial strains
tested: E. coli ATCC 25922, S. aureus ATCC 25923, P. aeruginosa ATCC 27853; control e medium infected with bacteria without
prostheses. Medium was exchanged daily and inoculated with bacteria to 1 102 CFU/ml. SDs were less than 8.9% in all cases.
704 M. Osin´ska-Jaroszuk et al.instead of non-modified ones. The disadvantage of this
concept lies in the fact that the currently proposed modi-
fied matrices usually undergo quick elution of antibacterial
agent from implanted matrix, thus leaving the material
unprotected against bacterial attack in the late
postoperative period.12
Apart from antibiotics, silver is also frequently applied
as another bactericidal substance. Silver is one of the
microbial agents that are active against virulent bacteria,
including MRSA, which are the leading cause of vascular
graft infections.11,33 Silver is also effective against burns,
chronic osteomyelitis and various infections15 and is
commercially used for decades for protection of vascular
prostheses.
In this study, we compared the antibacterial activity of
silver-impregnated vascular prostheses with grafts cova-
lently modified with aminoglycoside antibiotics. The supe-
riority of these prostheses over antibiotic-soaked materialsFigure 4 Growth of human skin fibroblasts (HSF) on UniGraft vas
gentamicin (B) and amikacin (C). Mag. 50.were shown in our research as they are able to retain the
majority of bound antibiotic on the prostheses even after
30 days of elution (Table 3). In comparison, rifampicin-
soaked prostheses released the whole amount of the
attached drug during the first 7 days of release test (Table 3).
Similarly, covalently modified vascular grafts were found to
be much more effective against many reference and clin-
ical bacteria than commercially available InterGard Silver
(Tables 4 and 5, Fig. 1). The diversity of clinical isolates
tested in our experiments seems to confirm the antibacte-
rial effectiveness of patented biomodification of implant-
able materials, thus suggesting that they may fight
postoperative infections caused by highly aggressive strains
muted at surgical tracts in hospitals. The resistance of
studied prostheses against MRSA strain is also highly
promising. It is worth noting that InterGard Silver, tested
against MRSA strain in our experiments, revealed only
short-lasting antibacterial effect, disappearing just aftercular prostheses non-modified (A) and covalently modified with
Vascular Prostheses with Covalently Bound Gentamicin and Amikacin 7057 days of continuous contact with bacterial suspension
(Table 4). Covalently (amikacin and gentamicin) modified
prostheses also protected the surrounding liquid (repre-
sented by the lack of biofilm on their surfaces; Fig. 2) from
bacterial attack for at least 1 month, without losing more
than 10% of the initially bound drug content in contrast to
InterGard Silver graft (Tables 4 and 5, Figs. 1e3). These
results are in agreement with the other study concerning
comparison of rifampin-bonded gelatin-sealed and silver/
collagen-impregnated prostheses and their antibacterial
activity. The authors found that InterGard Silver grafts
were less resistant against bacterial colonisation than
rifampin-soaked ones, despite the fact that rifampin was
only weakly attached to the prostheses.34 As antibacterial
effect of silver ions occurs only when the metal ions diffuse
from the matrix, thus penetrating bacterial cell walls and
turning DNA into a condensed form and denaturing enzymes
by attaching to thiol groups,15 it clearly appears that
majority of silver ions is released from the prostheses
within few days.
Some clinical observations confirm that InterGard
Silver prostheses are ineffective in combating heavy
infections. Surgeons suggest that they could be used in
primary operations, but vascular prostheses infected after
the implantation should be replaced using allogenic
implants.35,36
Gentamicin and amikacin have been rarely in use in the
recent years for their ototoxicity and renal toxicity and also
because stronger antibiotics such as rifampicin and vanco-
mycin were commonly used. However, emergence of muted
bacterial strains, resistant even to vancomycin, is often
a limiting factor in antibacterial prophylaxis. On vascular
surgery tracts in the Hospital Henri Mondor, France, the use
of rifampin in the procedure room is no longer allowed
because of the rise in rifampin-resistant S. aureus strains.27
In a dog model described in their study, rifampin released
from prostheses reached a subminimal bactericidal
concentration within several days after the implantation,
thereby creating an environment for the development of
resistance to this antibiotic.27 Moreover, as vancomycin has
recently become the first-line drug for the treatment of
MRSA; however, vancomycin-resistant strains of MRSA are
now emerging.37 Therefore, gentamicin and amikacin could
be effective in combating the postoperative bacterial
infections caused by vancomycin- and rifampin-resistant
microorganisms. Stable covalent modification of vascular
grafts by amikacin and gentamicin may reopen an old gate
to effective eradication of bacteria from graft-surrounding
tissues for months, and not just for a few days after the
implantation.
One may say that silver-impregnated grafts are thus
ineffective in comparison with those by antibiotics and
their production and used should be aborted. We would not
agree with such a statement. As a compound with a mode
of antibacterial action unlike that of antibiotics, it can play
a supporting role as a substance co-immobilised with
stable-bound antibiotics on the same prosthesis. Recently,
a concept of two antimicrobial agents used together on
vascular prostheses emerged as effective in antibacterial
protection of implantable biomaterials.13,14 In addition,
silver and rifampin adsorbed to vascular prostheses were
suggested to demonstrate a synergistic action with efficacyagainst all Gram-positive and -negative bacteria.27 The
modes of the action of antibacterial agents used in
presented experiments seemed to work in union to
decrease the risk of infection. It is possible that our future
work, concerning the uploading of silver-impregnated
prostheses with covalently immobilised aminoglycoside
antibiotics, could lead to creation of a more effective tool
for prevention of bacterial infections. Moreover, it is clear
that further tests concerning in vivo behaviour of cova-
lently modified antibiotics-bonded prostheses versus silver-
impregnated ones are necessary to fully evaluate their
potency at bacterial prevention during surgical operations.
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